BioCentury
ARTICLE | Clinical News

Solzira: Phase IIb data

September 21, 2009 7:00 AM UTC

Top-line data from a 14-week, double-blind Phase IIb trial in 376 PHN patients showed that 1,200, 2,400 and 3,600 mg/day Solzira met the primary endpoint of significantly reducing the 24-hour average pain intensity score from baseline to the end of maintenance treatment vs. placebo. Specifically, 1,200, 2,400 and 3,600 mg/day Solzira reduced pain intensity scores from baseline by 2.46 to 3.82 (p=0.013), 2.28 to 3.70 (p=0.029) and 2.81 to 3.66 (p=0.002), respectively, vs. a reduction of 1.67 to 4.66 for placebo. Solzira was well tolerated. ...